XT
STLN

XTX Topco’s Starling Oncology STLN Stock Holding History

XTX Topco’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90,346
Closed -$277K – 4708
2026
Q1 		$277K Buy
90,346
+43,824
+94% +$134K ﹤0.01% 2549
2025
Q4 		$166K Buy
+46,522
New +$173K ﹤0.01% 2463
2025
Q3 		– Sell
-49,443
Closed -$101K – 3286
2025
Q2 		$101K Sell
49,443
-6,255
-11% -$15.6K ﹤0.01% 1882
2025
Q1 		$63.5K Buy
55,698
+18,448
+50% +$14.3K ﹤0.01% 1960
2024
Q4 		$11.5K Buy
37,250
+12,141
+48% +$3.15K ﹤0.01% 2131
2024
Q3 		$8.21K Buy
25,109
+13,652
+119% +$5.66K ﹤0.01% 1946
2024
Q2 		$5.27K Sell
11,457
-16,048
-58% -$13.7K ﹤0.01% 1745
2024
Q1 		$43.5K Buy
27,505
+9,494
+53% +$18.1K 0.01% 1493
2023
Q4 		$36.7K Sell
18,011
-28,089
-61% -$48.7K 0.01% 1287
2023
Q3 		$64.5K Buy
+46,100
New +$47.7K 0.01% 1247

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco's STLN Position: Q2 2026 in Review

XTX Topco sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 90,346 shares — an estimated $277K sold.

XTX Topco first reported a position in STLN in Q3 2023 and held it in 10 quarters. The position peaked at $277K in Q1 2026. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • XTX Topco reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 90,346 Starling Oncology shares in Q2 2026, an estimated $277K.
  • XTX Topco first reported a position in Starling Oncology in Q3 2023 and held it in 10 quarters.
  • XTX Topco's Starling Oncology position peaked at $277K in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.